Compare ULCC & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULCC | DVAX |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2021 | 2004 |
| Metric | ULCC | DVAX |
|---|---|---|
| Price | $5.81 | $10.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $5.56 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 4.7M | 1.5M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,729,000,000.00 | $330,514,000.00 |
| Revenue This Year | $0.37 | $24.63 |
| Revenue Next Year | $14.59 | $15.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.77 | ★ 26.73 |
| 52 Week Low | $2.89 | $9.20 |
| 52 Week High | $10.26 | $14.63 |
| Indicator | ULCC | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 78.64 | 48.59 |
| Support Level | $4.71 | $10.71 |
| Resistance Level | $6.02 | $11.00 |
| Average True Range (ATR) | 0.33 | 0.26 |
| MACD | 0.15 | -0.06 |
| Stochastic Oscillator | 90.28 | 22.63 |
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.